Adolphson P, Abbaszadegan H, Jonsson U, Dalén N, Sjöberg H E, Kalén S
Department of Orthopedics, Danderyd Hospital, Sweden.
Arch Orthop Trauma Surg. 1993;112(3):127-30. doi: 10.1007/BF00449987.
In a randomized double-blind study involving 42 postmenopausal women with a displaced Colles' fracture, we investigated whether piroxicam, a nonsteroid anti-inflammatory drug, can reduce posttraumatic osteopenia and improve the rate of recovery. In an earlier study [3] we found a bone-sparing effect caused by piroxicam after external fixation of the rabbit hindleg. The patients were treated with a below-elbow paster slab for 4 weeks after the reduction. The bone mineral content of the forearm bones was measured with a single-photon absorptiometer 8 weeks after the fracture. There was a mean 7% bone mineral decrease in the radius and 5% in the ulna among the patients treated with piroxicam versus 10% in the radius and 7% in the ulna in the placebo group. However, this difference was not significant. Piroxicam did not decrease the rate of fracture healing. The patients who received piroxicam had significantly less pain during plaster treatment, but there was no difference in the rate of functional recovery between the groups.
在一项涉及42名患有Colles骨折移位的绝经后女性的随机双盲研究中，我们调查了非甾体抗炎药吡罗昔康是否能减少创伤后骨质减少并提高恢复率。在早期的一项研究[3]中，我们发现吡罗昔康在兔后肢外固定后具有保骨作用。复位后，患者用肘下石膏托治疗4周。骨折8周后，用单光子吸收仪测量前臂骨的骨矿物质含量。服用吡罗昔康的患者桡骨骨矿物质平均减少7%，尺骨减少5%，而安慰剂组桡骨减少10%，尺骨减少7%。然而，这种差异并不显著。吡罗昔康并未降低骨折愈合率。接受吡罗昔康治疗的患者在石膏治疗期间疼痛明显减轻，但两组之间功能恢复率没有差异。
